Journal of Hematology and Oncology Research

The Open Access Pub has the reputation for quick reviewing and publishing original research articles. The editorial boards of our journals have many dedicated and reputed scientists as editorial members. Their support helps many researchers from all countries to enhance their research between scientists of various communities. This platform plays a crucial role in promoting science networks and exchanges.

Hematology and Oncology Research-Myelodysplastic syndrome-Radu Bucur Gologan

Romania

Fundeni Clinical Institute, Hematological Department

Send an Email

Radu Bucur Gologan

Address:

Sos Mihai Bravu nr 296, Bl 7, ap 8, sector 3, Bucharest

Research Interests:

  1. Myelodysplastic syndrome
  2. Acute and chronic leukemias
  3. Hereditary and acquired anemias
  4. Autoimmune hematological disorders
  5. Hodgkin and nonHodgkin lymphoma

Biography:

Publications:

  1. Epidemiological data on myelodysplastic syndrome patients under 50 years in a single center of Romania.
  2. Epidemiological data from the registry of patients with myelodysplastic syndrome in a single hospital center of Romania.
  3. Mixed myelodysplastic syndrome associated with β-thalassemia intermedia.
  4. Hemosiderinuria In Myelodysplastic Syndrome.
  5. Complete remission in Hodgkin's lymphoma documented after removal of mediastinal residual masses by video-assisted toracoscopy.
  6. Thoracic spinal cord compression secondary to extramedullary haematopoiesis in thalassaemia intermedia successfully treated by local radiotherapy and hydroxyurea: a case report and review of the literature.
  7. Large cells lymphoma in a case of chronic lymphocytic leukemia in remission after treatment with fludarabine (observations on a case and review of the literature).
  8. Multiple Myeloma In Remission Complicated By Bone Marrow Granulomas.
  9. Hypoplastic Myelodysplastic Syndrome Transformed In Acute Myeloid Leukemia After Androgens And Cyclosporin A Treatment.
  10. Remission Induction in Elderly Acute Myeloid Leukemia by Low-Dose Melphalan.